Abstract IA20: Circulating tumor cells: Biology and clinical applications as liquid biopsy

Author(s):  
Klaus Pantel
Author(s):  
Natalie Reimers ◽  
Klaus Pantel

Abstract“Liquid biopsy” was introduced as a new diagnostic concept in 2010 for the analysis of circulating tumor cells (CTCs) and has been now extended to material (in particular DNA) released by tumor cells in the peripheral blood of cancer patients. Over the past decade, various methods have been developed to detect CTCs and ctDNA in the peripheral blood of cancer patients.


2020 ◽  
Vol 10 (11) ◽  
pp. 3704
Author(s):  
Menno Tamminga ◽  
Harry J.M. Groen

As therapies have become more and more dependent on tumor as well as patient characteristics, obtaining tumor material has become of great importance. Liquid biopsies hold much potential as shown by a large amount of evidence across several studies. Clinical applications for circulating tumor cells (CTCs) are unfortunately still lacking. In part this is due to a lack of studies comparing liquid biopsies to conventional diagnostics and response measurements as well as studies showing that liquid biopsies can be used to switch therapies leading to improved outcomes. However, liquid biopsies using ctDNA for specific markers such as EGFR, ALK, ROS1 or RET have clinical applications because specific drugs are available.


Lab on a Chip ◽  
2020 ◽  
Vol 20 (21) ◽  
pp. 3854-3875 ◽  
Author(s):  
Haimeng Pei ◽  
Lu Li ◽  
Zhaojun Han ◽  
Yiguo Wang ◽  
Bo Tang

Microfluidic technologies for circulating tumor cells: from enrichment to single-cell analysis to liquid biopsy for clinical applications.


Sign in / Sign up

Export Citation Format

Share Document